Genomic Biomarkers and Underlying Mechanism of Benefit from BCG Immunotherapy in Non-Muscle Invasive Bladder Cancer - Diogo A. Bastos, Romulo L. Mattedi, Rodrigo Barreiro, Filipe F. dos Santos, Vanessa Buzatto, Cibele Masotti, Jussara M. Souza, Mariana Z. T. de Lima, Giulia W. Friguglietti, Carlos Dzik, Denis L. F. Jardim, Rafael Coelho, Leopoldo A. Ribeiro Filho, Maurício D. Cordeiro, William C. Nahas - Dissemin

Dissemin is shutting down on January 1st, 2025

Language
Login

Published in

Bladder Cancer, 2(6), p. 171-186, 2020

DOI: 10.3233/blc-200289

Links

Tools

Export citation

Search in Google Scholar

Genomic Biomarkers and Underlying Mechanism of Benefit from BCG Immunotherapy in Non-Muscle Invasive Bladder Cancer

Journal article published in 2020 by Diogo A. Bastos, Romulo L. Mattedi, Rodrigo Barreiro, Filipe F. dos Santos, Vanessa Buzatto, Cibele Masotti, Jussara M. Souza, Mariana Z. T. de Lima, Giulia W. Friguglietti, Carlos Dzik, Denis L. F. Jardim, Rafael Coelho, Leopoldo A. Ribeiro Filho, Maurício D. Cordeiro, William C. Nahas and other authors.

This paper was not found in any repository, but could be made available legally by the author.

This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle

Preprint: archiving allowed

Upload

Green circle

Postprint: archiving allowed

Upload

Red circle

Published version: archiving forbidden

Policy details

Data provided by

SHERPA/RoMEO